Table 1. Summary of the data used in the meta-analysis.
| First author | Year | Country | Drug | N of patient | Duration of treatment | Medication dose | Percentage change (%) of LDL-cholesterol level | Genotyping method | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TT | TC | CC | TT | TC | CC | |||||||
| Igel M | 2006 | Germany | Pravastatin | 8 | 8 | 3 weeks | 40 mg/day | -19.10±8.30 | -13.10±9.10 | PHASE program | ||
| Hedman M | 2006 | Finland | Pravastatin | 14 | 6 | - | 2 months | 10 mg/day | -20.10±10.20 | -23.20±11.60 | - | TaqMan |
| Zhang W | 2007 | China | Pravastatin | 36 | 9 | - | 30 days | 20 mg/day | -22.40±10.30 | -14.50±6.60 | - | PCR |
| Couvert P | 2008 | France | Fluvastatin | 305 | 110 | 5 | 2 months | 80 mg/day | -34.00±15.90 | -30.70±17.40 | -31.30±5.20 | TaqMan |
| Bailey KM | 2010 | United Kingdom | Simvastatin | 200 | 82 | 9 | 3 months | - | -79.52±25.36 | -77.77±25.25 | TaqMan | |
| Rosuvastatin | 231 | 72 | 7 | -73.24±23.41 | -76.34±20.85 | |||||||
| Yang GP | 2010 | China | Pitavastatin | 64 | 21 | 4 weeks | 2 mg/day | -31.00±21.00 | -30.00±26.00 | PCR-RFLP | ||
| ARMS-PCR | ||||||||||||
| Yang GP | 2010 | China | Pitavastatin | 64 | 21 | 8 weeks | 2 mg/day | -29.00±26.00 | -27.00±29.00 | PCR-RFLP | ||
| ARMS-PCR | ||||||||||||
| Sortica VA | 2012 | Brazil | Simvastatin | 152 | 59 | 5 | 6 months | 20 mg/day | -38.60±8.00 | -39.90±8.60 | -42.10±15.80 | TaqMan |
| Fu Q | 2013 | China | Atorvastatin | 133 | 49 | 7 | 4 weeks | 20 mg/day | -27.80±5.30 | -26.50±6.00 | -26.80±3.50 | AS-PCR |
| Simvastatin | 123 | 46 | 5 | -27.20±5.40 | -28.90±5.90 | -30.80±5.40 | RFLP | |||||
Please delete this line. These footnote belong to Fig. 2.
Abbreviations: ARMS, amplification refractory mutation system; AS, allele-specific; RFLP, restriction fragment length polymorphism.